New Treatment Identified for Advanced Breast Cancers
Researchers have discovered a strategy to target aggressive breast cancers that carry both HER2 and TP53 mutations.
Updated on Oct. 15, 2026 in Cancer
Scientists have identified that breast cancers featuring co-occurring HER2 and TP53 mutations are uniquely sensitive to topoisomerase I inhibitors. This discovery offers a new potential therapeutic path for patients with aggressive, resistant tumor types.
Why it matters
The presence of TP53 mutations frequently causes resistance to standard therapies like neratinib, making these cancers difficult to treat. Targeting the underlying chromatin accessibility changes triggered by these mutations could provide a vital new clinical option.
TP53 mutant tumors exhibit increased chromatin accessibility via histone acetylation and hypertranscription of DNA repair factors. This molecular profile creates a specific vulnerability to the topoisomerase I inhibitor exatecan.
The details
The research reveals that TP53 mutations fundamentally alter the cellular environment, increasing chromatin accessibility and triggering G2/M arrest when exposed to TOP1 inhibitors. While these tumors are resistant to traditional drugs like neratinib, they succumb to targeted treatment through the induction of apoptosis.
Timeline
October 15, 2026: The research findings were published.
The Big Picture
This discovery shifts the paradigm of HER2-positive cancer treatment by demonstrating that genetic co-mutations require a departure from standard targeted therapies. It suggests that future research into p53-mutated cancers, including triple-negative types, may successfully utilize TOP1-targeted inhibitors.
Patients with aggressive breast cancer harboring both HER2 and TP53 mutations may eventually benefit from new, highly specific therapeutic protocols. This development offers hope for improved outcomes where current standard-of-care drugs like neratinib fail.
The takeaway
Understanding the genetic interaction between HER2 and TP53 is essential for overcoming therapeutic resistance in breast cancer. Clinicians and researchers should prioritize identifying co-mutated tumor profiles to better match patients with effective TOP1-targeted inhibitors.
Further reading
For more on evolving treatment protocols, visit our Cancer section.
Source note: This article includes information reported by Nature.
